DOCSLIB.ORG

Hyperhomocysteinemia: How Does It Affect the Development of Cardiovascular Disease?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hyperhomocysteinemia: How Does It Affect the Development of Cardiovascular Disease? ISSN: 2643-3966 Lopes. Int Arch Cardiovasc Dis 2018, 2:008 Volume 2 | Issue 1 Open Access International Archives of Cardiovascular Diseases REVIEW ARTICLE Hyperhomocysteinemia: How Does it Affect the Development of Cardiovascular Disease? * Lopes Cardoso I Check for updates Health Sciences Faculty, Fernando Pessoa University, Portugal *Corresponding author: Inês Lopes Cardoso, Health Sciences Faculty, Fernando Pessoa University, Rua Carlos da Maia, 296, 4200-150 Porto, Portugal, Tel: 351-225071300 of the ones having atherosclerotic vascular disease, 13- Abstract 47% show moderate to intermediate hyperhomocyste- Homocysteine is an amino acid with an SH group, metab- ine levels [1,2]. olised by the remethylation and transsulfuration pathways. Several genetic and environmental factors (like deficient Changes in plasma homocysteine levels can result nutrition status, systemic disease or consumption of certain from the presence of several factors including physio- drugs), can lead to changes in the levels of plasma homo- cysteine. logical, genetic, nutritional, drug induced and hormonal factors. First studies indicating mild hyperhomocyste- Nowadays, hyperhomocysteinemia is considered an impor- tant and independent risk factor for atherosclerosis and car- inemia as an independent risk factor for cardiovascular diovascular disease. disease, with a prevalence of approximately 5% in the general population, date from the 80th decade [3-6]. Several pathological mechanisms have been proposed for the effect of hyperhomocysteinemia in the development of Metabolism of Homocysteine cardiovascular disease. Among them are DNA methylation, decreased protein S-nitrosylation, production of reactive ox- Homocysteine is an amino acid with SH group, pro- idative species and decrease in nitric oxide formation. duced exclusively from methionine which, as an essen- Main strategies being tested for the treatment of this condi- tial amino acid, comes from food diet [7]. Homocysteine tion involve supplementation of folic acid, vitamins B6, B12 metabolism involves two different metabolic pathways: or riboflavin. From these, increased plasma folic acid lev- the remethylation and the transsulfuration pathways els by folate-rich diet or pharmacological supplementation seems to be the most effective. (Figure 1) [8,9]. Keywords The remethylation pathway, mainly occurring in Homocysteine, Cardiovascular disease, Folic acid, Vitamin starvation conditions, involves the catabolism of -me B6, Vitamin B12, Riboflavin thionine. In the first step, methionine reacts with ATP leading to the formation of S-adenosylmethionine. This molecule then loses the methyl group attached with Introduction the sulphur atom (present in methionine), forming S-adenosyl-homocysteine. The methyl group released Cardiovascular diseases are the main cause of death by S-adenosylmethionine can be transferred by meth- in developed countries. Several risk factors are involved yl-transferases to several substrates (methyl acceptors) in its development like family background, hypercholes- like proteins, DNA or phospholipids (Figure 1). terolemia, obesity, diabetes mellitus and environmental factors such as sedentarism. High level of plasma ho- The next step is the hydrolysis of S-adenosyl-homo- mocysteine also represents a risk factor, independent cysteine to produce homocysteine. Later, the sulphur of other factors. It is observed that 5-7% of general atom of homocysteine can be transferred to serine en- population show hyperhomocysteinemia, and of those, tering the transsulfuration pathway described below. Citation: Lopes CI (2018) Hyperhomocysteinemia: How Does it Affect the Development of Cardiovas- cular Disease?. Int Arch Cardiovasc Dis 2:008 Accepted: August 25, 2018; Published: August 27, 2018 Copyright: © 2018 Lopes CI. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Lopes. Int Arch Cardiovasc Dis 2018, 2:008 • Page 1 of 12 • ISSN: 2643-3966 Methionine cycle Folate cycle Food diet Serine Remeth ylation pathway Methionin Tetrahydro folate Glycine S-adenosylmethionine Methionine 5,10-methylene Methylated acceptor Vitamin B12 synthetase tetrahydrofolate Methyl a cceptor S-adenosyl-homocysteine MTHFR + NADP Homocysteine 5-Methyl Riboflavin tetrahydrofolate Vitamin B6 Cystathionine-β-synthase NADPH Cystathionine Tran ssulfuration pathway Cysteine Sulphate Urine Figure 1: Homocysteine metabolism (adapted from [10]). Homocysteine can also be used to regenerate methi- sequentially involved: Cystathionine β-synthase (CBS) onine, by the vitamin B12 dependent enzyme methi- and cystathionine lyase. The active form of vitamin B6 - onine synthetase (MS) that transfers a methyl group pyridoxal phosphate - is a cofactor of CBS that converts given by 5-methyltetrahydrofolate to homocysteine. homocysteine into cystathionine, first step of the trans- In most cells, this is the main or unique pathway of sulfuration pathway (Figure 1). The α-ketobutirate can conversion of homocysteine to methionine. This ami- be converted into propionyl-CoA that is further trans- no acid will enter a new cycle of donation of methyl formed into succinyl-CoA (an intermediate of the Krebs group. Another product of this reaction is tetrahydro- cycle). It is evident the importance of B vitamins in ho- folate, that will be reconverted to 5-methyltetrahydro- mocysteine metabolism, since these molecules play a folate through the folate cycle, where the conversion crucial role as enzyme cofactors. Vitamin B6 is required of 5,10-methylenetetrahydrofolate to 5-methyltetrahy- for CBS activity while vitamin B12 is the cofactor of MS. drofolate is catalysed by the FAD dependent enzyme, Another important vitamin for homocysteine metabo- methylenetetrahydrofolate reductase (MTHFR) [10]. lism is riboflavin that is necessary for MTHFR function. MTHFR enzyme has an important function since it reg- Homocysteine can be found in plasma in the free ulates the availability of 5-methyltetrahydrofolate for form (around 20-30%), but most of it (70-80%) is associ- homocysteine remethylation. The reaction catalysed by ated with plasma proteins, mainly albumin. MS allows the connection between the methionine and the folate cycles (Figure 1). Plasma homocysteine present in the free form can also be in the oxidized form, giving rise to two types The transsulfuration pathway, that takes place in of disulphides: Homocysteine dimers (homocystine) or cases of methionine overload, involves the catabo- homocysteine-cysteine dimers. From the free homocys- lism of homocysteine to sulphate, later excreted in the teine fraction, 2 to 5% correspond to its reduced form. urine. The sulphur atom present in homocysteine is Total plasma homocysteine is the sum of all free forms transferred to serine leading to the production of cyste- and forms attached to proteins [11]. ine, while the nitrogenated group and the carbons that belonged to homocysteine are released as ammonium Concerning plasma homocysteine levels, there is no and α-ketobutirate. In this process, two enzymes are consensus about the upper standard limits for healthy Lopes. Int Arch Cardiovasc Dis 2018, 2:008 • Page 2 of 12 • ISSN: 2643-3966 individuals, ranging from 5 to 15 µmol/L [2,12,13]. How- Li, et al. [25] detected eleven mutations and ever, some studies have shown that an upper limit of eight (IVS3+1G>A, p.T493fsX46, p.T236N, p.L230Q, p. 15 µmol/L is too high in well-nourished populations K72I, p.S201ProfsX36, p.M337IfsX115 and IVS14-1G>C) without vitamin deficiencies [14]. Moreover, plasma were novel. The remaining three mutations (p.R125Q, homocysteine concentrations vary with age and gender p.T257M and p.G116R) had been previously reported [12,13]. [25]. It has been documented the existence of substan- Moreover, Voskoboeva, et al. [26] detected one tial cardiovascular risk with plasma homocysteine lev- new nonsense mutation (Q368Term), one new mis- els between 10 and 15 µmol/L. However, on the other sense mutation (р.D444Y) and three novel small dele- hand, de Bree, et al. [15] observed that an increase of tions (c.1560-1569delCACCGGGAAG; c.216-217delAT; 5 µmol/L in plasma homocysteine concentration, rises c.1498-1499delT) in Russian patients. 1.03 the risk of coronary heart disease mortality. These Other rare genetic changes can cause an up to 20 results do not support the idea of an influence of hy- times increase in plasma homocysteine and lead to perhomocysteinemia in increased risk of cardiovascular the development of severe hyperhomocysteinemia disease [15]. and result from deficiency in the MTHFR enzyme of Genetic Factors Involved in the Development the remethylation pathway and 10 different mutations of Hyperhomocysteinemia in this gene have already been described (located at 1p36.3) [18,19]. The clinical syndrome homocystinuria, identified al- most 60 years ago [16,17], is a disorder with autosomal The major known genetic determinant of mild hyper- recessive transmission. Phenotypic characteristics in- homocysteinemia in the general population is a thermo- clude thromboembolism and vascular occlusion, chang- labile missense mutation, that leads to the change of al- es in long bones, ocular displacement, mental retarda- anine per valine, resulting from the substitution of cyto- tion and varying degrees of neurological impairment sine per thymine in base 677 of the gene. This mutation [10,18,19]. leads
Load more

Recommended publications
  • Involvements of Hyperhomocysteinemia in Neurological Disorders
    H OH metabolites OH Review Involvements of Hyperhomocysteinemia in Neurological Disorders Marika Cordaro 1,† , Rosalba Siracusa 2,† , Roberta Fusco 2 , Salvatore Cuzzocrea 2,3,* , Rosanna Di Paola 2,* and Daniela Impellizzeri 2 1 Department of Biomedical, Dental and Morphological and Functional Imaging, University of Messina, Via Consolare Valeria, 98125 Messina, Italy; [email protected] 2 Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy; [email protected] (R.S.); [email protected] (R.F.); [email protected] (D.I.) 3 Department of Pharmacological and Physiological Science, Saint Louis University School of Medicine, Saint Louis, MO 63104, USA * Correspondence: [email protected] (S.C.); [email protected] (R.D.P.); Tel.: +39-090-6765208 (S.C. & R.D.P.) † The authors equally contributed to the review. Abstract: Homocysteine (HCY), a physiological amino acid formed when proteins break down, leads to a pathological condition called hyperhomocysteinemia (HHCY), when it is over a definite limit. It is well known that an increase in HCY levels in blood, can contribute to arterial damage and several cardiovascular disease, but the knowledge about the relationship between HCY and brain disorders is very poor. Recent studies demonstrated that an alteration in HCY metabolism or a deficiency in folate or vitamin B12 can cause altered methylation and/or redox potentials, that leads to a modification on calcium influx in cells, or into an accumulation in amyloid and/or tau protein involving a cascade of events that culminate in apoptosis, and, in the worst conditions, neuronal death. The present review will thus summarize how much is known about the possible role of HHCY in neurodegenerative disease.
    [Show full text]
  • Amino Acid Disorders
    471 Review Article on Inborn Errors of Metabolism Page 1 of 10 Amino acid disorders Ermal Aliu1, Shibani Kanungo2, Georgianne L. Arnold1 1Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA Contributions: (I) Conception and design: S Kanungo, GL Arnold; (II) Administrative support: S Kanungo; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: E Aliu, GL Arnold; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Georgianne L. Arnold, MD. UPMC Children’s Hospital of Pittsburgh, 4401 Penn Avenue, Suite 1200, Pittsburgh, PA 15224, USA. Email: [email protected]. Abstract: Amino acids serve as key building blocks and as an energy source for cell repair, survival, regeneration and growth. Each amino acid has an amino group, a carboxylic acid, and a unique carbon structure. Human utilize 21 different amino acids; most of these can be synthesized endogenously, but 9 are “essential” in that they must be ingested in the diet. In addition to their role as building blocks of protein, amino acids are key energy source (ketogenic, glucogenic or both), are building blocks of Kreb’s (aka TCA) cycle intermediates and other metabolites, and recycled as needed. A metabolic defect in the metabolism of tyrosine (homogentisic acid oxidase deficiency) historically defined Archibald Garrod as key architect in linking biochemistry, genetics and medicine and creation of the term ‘Inborn Error of Metabolism’ (IEM). The key concept of a single gene defect leading to a single enzyme dysfunction, leading to “intoxication” with a precursor in the metabolic pathway was vital to linking genetics and metabolic disorders and developing screening and treatment approaches as described in other chapters in this issue.
    [Show full text]
  • Abstracts from the 50Th European Society of Human Genetics Conference: Electronic Posters
    European Journal of Human Genetics (2019) 26:820–1023 https://doi.org/10.1038/s41431-018-0248-6 ABSTRACT Abstracts from the 50th European Society of Human Genetics Conference: Electronic Posters Copenhagen, Denmark, May 27–30, 2017 Published online: 1 October 2018 © European Society of Human Genetics 2018 The ESHG 2017 marks the 50th Anniversary of the first ESHG Conference which took place in Copenhagen in 1967. Additional information about the event may be found on the conference website: https://2017.eshg.org/ Sponsorship: Publication of this supplement is sponsored by the European Society of Human Genetics. All authors were asked to address any potential bias in their abstract and to declare any competing financial interests. These disclosures are listed at the end of each abstract. Contributions of up to EUR 10 000 (ten thousand euros, or equivalent value in kind) per year per company are considered "modest". Contributions above EUR 10 000 per year are considered "significant". 1234567890();,: 1234567890();,: E-P01 Reproductive Genetics/Prenatal and fetal echocardiography. The molecular karyotyping Genetics revealed a gain in 8p11.22-p23.1 region with a size of 27.2 Mb containing 122 OMIM gene and a loss in 8p23.1- E-P01.02 p23.3 region with a size of 6.8 Mb containing 15 OMIM Prenatal diagnosis in a case of 8p inverted gene. The findings were correlated with 8p inverted dupli- duplication deletion syndrome cation deletion syndrome. Conclusion: Our study empha- sizes the importance of using additional molecular O¨. Kırbıyık, K. M. Erdog˘an, O¨.O¨zer Kaya, B. O¨zyılmaz, cytogenetic methods in clinical follow-up of complex Y.
    [Show full text]
  • Congenital Ocular Anomalies in Newborns: a Practical Atlas
    www.jpnim.com Open Access eISSN: 2281-0692 Journal of Pediatric and Neonatal Individualized Medicine 2020;9(2):e090207 doi: 10.7363/090207 Received: 2019 Jul 19; revised: 2019 Jul 23; accepted: 2019 Jul 24; published online: 2020 Sept 04 Mini Atlas Congenital ocular anomalies in newborns: a practical atlas Federico Mecarini1, Vassilios Fanos1,2, Giangiorgio Crisponi1 1Neonatal Intensive Care Unit, Azienda Ospedaliero-Universitaria Cagliari, University of Cagliari, Cagliari, Italy 2Department of Surgery, University of Cagliari, Cagliari, Italy Abstract All newborns should be examined for ocular structural abnormalities, an essential part of the newborn assessment. Early detection of congenital ocular disorders is important to begin appropriate medical or surgical therapy and to prevent visual problems and blindness, which could deeply affect a child’s life. The present review aims to describe the main congenital ocular anomalies in newborns and provide images in order to help the physician in current clinical practice. Keywords Congenital ocular anomalies, newborn, anophthalmia, microphthalmia, aniridia, iris coloboma, glaucoma, blepharoptosis, epibulbar dermoids, eyelid haemangioma, hypertelorism, hypotelorism, ankyloblepharon filiforme adnatum, dacryocystitis, dacryostenosis, blepharophimosis, chemosis, blue sclera, corneal opacity. Corresponding author Federico Mecarini, MD, Neonatal Intensive Care Unit, Azienda Ospedaliero-Universitaria Cagliari, University of Cagliari, Cagliari, Italy; tel.: (+39) 3298343193; e-mail: [email protected].
    [Show full text]
  • Analysis of Body Composition and Nutritional Status in Brazilian Phenylketonuria Patients
    Molecular Genetics and Metabolism Reports 6 (2016) 16–20 Contents lists available at ScienceDirect Molecular Genetics and Metabolism Reports journal homepage: www.elsevier.com/locate/ymgmr Analysis of body composition and nutritional status in Brazilian phenylketonuria patients Priscila Nicolao Mazzola a,b, Tatiele Nalin c,⁎, Kamila Castro d,MargreetvanRijnb, Terry G.J. Derks b, Ingrid D.S. Perry e, Alberto Scofano Mainieri f, Ida Vanessa D. Schwartz c,g,h a Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Universidade Federal do Rio Grande do Sul (UFRGS), Ramiro Barcelos 2600 anexo, 90035-003, Porto Alegre, Brazil b Beatrix Children's Hospital, Section of Metabolic Diseases, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands c Post-Graduation Program in Genetics and Molecular Biology, UFRGS, Bento Gonçalves 9500/43323M, PO Box 15053, Porto Alegre, Brazil d Postgraduate Program in Pediatrics and Adolescent Health, UFRGS, Ramiro Barcelos 2400, 90035-003, Porto Alegre, Brazil e Postgraduate Program in Collective Health, Health Unit, Universidade do Extremo Sul Catarinense, Universitária 1105, 88806-000 Criciúma, Brazil f Department of Pediatrics, Hospital de Clínicas de Porto Alegre, Ramiro Barcelos 2400, 90035-003 Porto Alegre, Brazil g Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos 2350, 90035-003 Porto Alegre, Brazil h Department of Genetics, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos 2350, 90035-003 Porto Alegre, Brazil article info abstract Article history: Background: Phenylketonuria (PKU) is characterized by phenylalanine (Phe) accumulation to toxic levels due to Received 20 November 2015 the low activity of phenylalanine-hydroxylase.
    [Show full text]
  • MILD HYPERHOMOCYSTEINEMIA and ARTERIAL OCCLUSIVE DISEASE JACOB SELHUB USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA
    Journal of Hematology volume 82 – number 2 – March-April 1997 editorial MILD HYPERHOMOCYSTEINEMIA AND ARTERIAL OCCLUSIVE DISEASE JACOB SELHUB USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA he initial link between homocysteine and vas- ic vascular disease, with odds ratios for a 5 umol/L cular disease was made by McCully approxi- increase in plasma tHcy that were equal to 1.5-1.8 Tmately 25 years ago.1 He observed that an for men and women with CHD, cerebrovascular or infant who died as a result of a rare genetic condi- peripheral vascular diseases. tion of abnormal cobalamin metabolism with Our interest in homocysteine was prompted by homocystinuria exhibited widespread, severe arte- the possibility that plasma homocysteine may serve riosclerosis analogous to the lesions seen in cases of as an indicator of the status and perhaps the intake homocystinuria caused by a genetic cystathionine of a number of vitamins, including folic acid, vita- ␤-synthase deficiency. Because hyperhomocysteine- min B12 and vitamin B6. This possibility derived mia was the only condition common to these two from the large number of studies which implied metabolic disorders, McCully proposed that hyper- that methionine metabolism is tightly regulated,3,6,7 homocysteinemia resulted in arteriosclerotic dis- and from other studies which showed that deficien- ease. Although McCully’s hypothesis did not gain cies in the above vitamins are often associated with immediate support, the association between plas- hyperhomocysteinemia.8-18 ma homocysteine concentration and arteriosclero- The aims of our studies were therefore: 1) to sis has more recently become the subject of a num- determine the relationship between plasma homo- ber of clinical studies.
    [Show full text]
  • Defects in Amino Acid Catabolism and the Urea Cycle
    Handbook of Clinical Neurology, Vol. 113 (3rd series) Pediatric Neurology Part III O. Dulac, M. Lassonde, and H.B. Sarnat, Editors © 2013 Elsevier B.V. All rights reserved Chapter 181 Defects in amino acid catabolism and the urea cycle GEORG F. HOFFMANN* AND STEFAN KO¨ LKER Department of General Pediatrics, University Children’s Hospital Heidelberg, Heidelberg, Germany INTRODUCTION organizations can offer support. Since treatment is time- and cost-intensive, often lifelong, and mostly Defects in amino acid catabolism and the urea cycle performed at home, regular training and support of result in an accumulation of metabolites upstream of patients and their families is essential. Unfortunately, as the defective enzyme (amino acids (AAs), organic acids for all chronic diseases, average compliance with recom- and/or ammonia) causing intoxication. Phenylketonuria mendations has been found as low as 50%, e.g., in PKU. (PKU) is the most frequent AA disorder (AAD) in Individual defects in AA catabolism and the urea Caucasians. Breakdown of AAs results in the release cycle usually have a low prevalence except for some of ammonia that is detoxified by the urea cycle. Hyper- communities with high consanguinity rates. However, ammonemia is the biochemical hallmark of urea cycle the cumulative prevalence of these disorders is consider- defects (UCDs). able (i.e., at least> 1:2000 newborns; Schulze et al., After an uneventful pregnancy and an initially asymp- 2003). Detailed information on diagnosis, genetic test- tomatic period, the onset of symptoms in these disorders ing, treatment and follow-up is available at the following varies from neonatal metabolic decompensation to late online databases: onset in adulthood.
    [Show full text]
  • Laboratory Diagnostic Approaches in Metabolic Disorders
    470 Review Article on Inborn Errors of Metabolism Page 1 of 14 Laboratory diagnostic approaches in metabolic disorders Ruben Bonilla Guerrero1, Denise Salazar2, Pranoot Tanpaiboon2,3 1Formerly Quest Diagnostics, Inc., Ruben Bonilla Guerrero, Rancho Santa Margarita, CA, USA; 2Quest Diagnostics, Inc., Denise Salazar and Pranoot Tanpaiboon, San Juan Capistrano, CA, USA; 3Genetics and Metabolism, Children’s National Rare Disease Institute, Washington, DC, USA Contributions: (I) Conception and design: All authors; (II) Administrative support: R Bonilla Guerrero; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Ruben Bonilla Guerrero. Formerly Quest Diagnostics, Inc., Ruben Bonilla Guerrero, 508 Sable, Rancho Santa Margarita, CA 92688, USA. Email: [email protected]. Abstract: The diagnosis of inborn errors of metabolism (IEM) takes many forms. Due to the implementation and advances in newborn screening (NBS), the diagnosis of many IEM has become relatively easy utilizing laboratory biomarkers. For the majority of IEM, early diagnosis prevents the onset of severe clinical symptoms, thus reducing morbidity and mortality. However, due to molecular, biochemical, and clinical variability of IEM, not all disorders included in NBS programs will be detected and diagnosed by screening alone. This article provides a general overview and simplified guidelines for the diagnosis of IEM in patients with and without an acute metabolic decompensation, with early or late onset of clinical symptoms. The proper use of routine laboratory results in the initial patient assessment is also discussed, which can help guide efficient ordering of specialized laboratory tests to confirm a potential diagnosis and initiate treatment as soon as possible.
    [Show full text]
  • Blueprint Genetics Hyperammonemia and Urea Cycle Disorder Panel
    Hyperammonemia and Urea Cycle Disorder Panel Test code: ME1601 Is a 49 gene panel that includes assessment of non-coding variants. Is ideal for patients with hyperammonemia or a clinical suspicion of a disorder of urea cycle metabolism. The genes on this panel are included in the Comprehensive Metabolism Panel. About Hyperammonemia and Urea Cycle Disorder Congenital urea cycle disorders are the result of defects in the metabolism of nitrogen waste. Deficiency of any of the enzymes in the urea cycle results in an excess of ammonia or other precursor metabolites in the blood. Normally, urea production lowers the ammonia levels in the blood but in the case of defective enzymes, the urea cycle is disturbed. Infants with urea cycle disorders (UCDs) develop cerebral edema, lethargy, hypothermia, neurologic signs and coma, often shortly after birth. Partial, or milder, UCDs are possible if the affected enzyme is positioned in a later phase of the urea cycle. Patients with UCDs may present with hyperammonemia often triggered by stress or illness. The most common primary hyperammonemia is X-linked recessive ornithine transcarbamylase deficiency caused by mutations in the OTC gene. The estimated prevalence is 1:56,000. Prevalence estimates for the other specific urea cycle disorders are 1:200,000 for ASL- and ASS1-related deficiencies and <1:1,000,000 for ARG1, CPS1 and NAGS-related deficiencies. The diagnostic yield ranges from 50% to 80% for different primary urea cycle disorders. In addition to congenital UCDs, this panel has the ability to diagnose other diseases of early phase hyperammonemia and other inborn errors of metabolism showing similar and overlapping symptoms.
    [Show full text]
  • Diseases Catalogue
    Diseases catalogue AA Disorders of amino acid metabolism OMIM Group of disorders affecting genes that codify proteins involved in the catabolism of amino acids or in the functional maintenance of the different coenzymes. AA Alkaptonuria: homogentisate dioxygenase deficiency 203500 AA Phenylketonuria: phenylalanine hydroxylase (PAH) 261600 AA Defects of tetrahydrobiopterine (BH 4) metabolism: AA 6-Piruvoyl-tetrahydropterin synthase deficiency (PTS) 261640 AA Dihydropteridine reductase deficiency (DHPR) 261630 AA Pterin-carbinolamine dehydratase 126090 AA GTP cyclohydrolase I deficiency (GCH1) (autosomal recessive) 233910 AA GTP cyclohydrolase I deficiency (GCH1) (autosomal dominant): Segawa syndrome 600225 AA Sepiapterin reductase deficiency (SPR) 182125 AA Defects of sulfur amino acid metabolism: AA N(5,10)-methylene-tetrahydrofolate reductase deficiency (MTHFR) 236250 AA Homocystinuria due to cystathionine beta-synthase deficiency (CBS) 236200 AA Methionine adenosyltransferase deficiency 250850 AA Methionine synthase deficiency (MTR, cblG) 250940 AA Methionine synthase reductase deficiency; (MTRR, CblE) 236270 AA Sulfite oxidase deficiency 272300 AA Molybdenum cofactor deficiency: combined deficiency of sulfite oxidase and xanthine oxidase 252150 AA S-adenosylhomocysteine hydrolase deficiency 180960 AA Cystathioninuria 219500 AA Hyperhomocysteinemia 603174 AA Defects of gamma-glutathione cycle: glutathione synthetase deficiency (5-oxo-prolinuria) 266130 AA Defects of histidine metabolism: Histidinemia 235800 AA Defects of lysine and
    [Show full text]
  • Bone Health in Patients with Inborn Errors of Metabolism
    Reviews in Endocrine and Metabolic Disorders (2018) 19:81–92 https://doi.org/10.1007/s11154-018-9460-5 Bone health in patients with inborn errors of metabolism M. Langeveld1 & C. E. M. Hollak1 Published online: 12 September 2018 # The Author(s) 2018 Abstract Inborn errors of metabolism encompass a wide spectrum of disorders, frequently affecting bone. The most important metabolic disorders that primarily influence calcium or phosphate balance, resulting in skeletal pathology, are hypophosphatemic rickets and hypophosphatasia. Conditions involving bone marrow or affecting skeletal growth and development are mainly the lyso- somal storage disorders, in particular the mucopolysaccharidoses. In these disorders skeletal abnormalities are often the present- ing symptom and early recognition and intervention improves outcome in many of these diseases. Many disorders of interme- diary metabolism may impact bone health as well, resulting in higher frequencies of osteopenia and osteoporosis. In these conditions factors contributing to the reduced bone mineralization can be the disorder itself, the strict dietary treatment, reduced physical activity or sunlight exposure and/or early ovarian failure. Awareness of these primary or secondary bone problems amongst physicians treating patients with inborn errors of metabolism is of importance for optimization bone health and recognition of skeletal complications. Keywords Osteopenia . Osteoporosis . Inborn error of metabolism . Lysosomal storage disorder . Skeletal dysplasia . Bone metabolism 1 Introduction
    [Show full text]
  • Arginase As a Potential Biomarker of Disease Progression: a Molecular Imaging Perspective
    International Journal of Molecular Sciences Review Arginase as a Potential Biomarker of Disease Progression: A Molecular Imaging Perspective Gonçalo S. Clemente 1 , Aren van Waarde 1, Inês F. Antunes 1, Alexander Dömling 2 and Philip H. Elsinga 1,* 1 Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands; [email protected] (G.S.C.); [email protected] (A.v.W.); [email protected] (I.F.A.) 2 Department of Drug Design, Groningen Research Institute of Pharmacy, University of Groningen, 9713 AV Groningen, The Netherlands; [email protected] * Correspondence: [email protected]; Tel.: +31-50-361-3247 Received: 2 July 2020; Accepted: 23 July 2020; Published: 25 July 2020 Abstract: Arginase is a widely known enzyme of the urea cycle that catalyzes the hydrolysis of L-arginine to L-ornithine and urea. The action of arginase goes beyond the boundaries of hepatic ureogenic function, being widespread through most tissues. Two arginase isoforms coexist, the type I (Arg1) predominantly expressed in the liver and the type II (Arg2) expressed throughout extrahepatic tissues. By producing L-ornithine while competing with nitric oxide synthase (NOS) for the same substrate (L-arginine), arginase can influence the endogenous levels of polyamines, proline, and NO•. Several pathophysiological processes may deregulate arginase/NOS balance, disturbing the homeostasis and functionality of the organism. Upregulated arginase expression is associated with several pathological processes that can range from cardiovascular, immune-mediated, and tumorigenic conditions to neurodegenerative disorders. Thus, arginase is a potential biomarker of disease progression and severity and has recently been the subject of research studies regarding the therapeutic efficacy of arginase inhibitors.
    [Show full text]